Skip to content

Study · Systematic review · 2025

4 results

Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials.

Jiang G, Yang X, Zhu G, Liu T

Aging clinical and experimental research5 May 2025Cited by 4 (Europe PMC)

PMID40325308 (opens in a new tab)PMCIDPMC12053337 (opens in a new tab)DOI10.1007/s40520-025-03017-4 (opens in a new tab)PepBankPUB-40325308
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In reviewed patients with obesity and knee osteoarthritis, semaglutide reduced WOMAC pain score versus usual care (MD -0.90,95% CI -1.48 to -0.32); units and analyzed N were unstated.

    In plain wordsIn obese people with knee osteoarthritis, semaglutide improved pain more than usual care.

    Peptide
    Semaglutide
    Outcome
    DecreaseWOMAC pain score
    Study

    n: not reported in source

    Comparator
    Usual care
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Pain MD
    −0.9
    semaglutide versus usual care
    95% CI
    −1.48 to −0.32
    WOMAC pain MD

    Source sentences

    Summary
    For pain relief, metformin demonstrated the largest effect size with a mean difference of - 1.13 (95% CI - 1.48, - 0.78) compared to usual care, followed by Metformin-Phosphatidylcholine (MFPH) (- 0.92, 95% CI - 1.70, - 0.13) and semaglutide (- 0.90, 95% CI - 1.48, - 0.32).
    4 context sentences
    Summary · context
    This study aimed to compare the efficacy and safety of antidiabetic drugs for managing pain and adverse events in obese KOA patients through a network meta-analysis of randomized controlled trials (RCTs).
    Summary · context
    A systematic search of multiple databases identified relevant RCTs on antidiabetic drugs for KOA.
    Summary · context
    Treatment efficacy was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score improvement, and safety was evaluated based on the incidence of serious adverse events.
    Summary · context
    The Surface Under the Cumulative Ranking Curve (SUCRA) scores were used to rank the treatments, and effect sizes were reported as mean differences (MD) with 95% confidence intervals (CI).
  2. 02HumanSystematic reviewSafety outcome

    In reviewed patients with obesity and knee osteoarthritis, liraglutide showed a favourable serious-adverse-event safety profile (printed effect 0.09,95% CI -0.74 to 0.92); original reference, signed clinical direction and effect units were unstated.

    In plain wordsIn obesity and knee osteoarthritis, liraglutide showed a favourable safety profile; the signed effect and original comparison were unstated.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedAdverse event risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Printed safety effect
    0.09
    original effect reference and units unstated
    95% CI
    −0.74 to 0.92
    safety effect

    Source sentences

    Summary
    In terms of safety, usual care exhibited the lowest risk of adverse events, with liraglutide (0.09, 95% CI - 0.74, 0.92) and semaglutide (0.21, 95% CI - 0.46, 0.88) also showing favorable safety profiles.
    4 context sentences
    Summary · context
    This study aimed to compare the efficacy and safety of antidiabetic drugs for managing pain and adverse events in obese KOA patients through a network meta-analysis of randomized controlled trials (RCTs).
    Summary · context
    A systematic search of multiple databases identified relevant RCTs on antidiabetic drugs for KOA.
    Summary · context
    Treatment efficacy was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score improvement, and safety was evaluated based on the incidence of serious adverse events.
    Summary · context
    The Surface Under the Cumulative Ranking Curve (SUCRA) scores were used to rank the treatments, and effect sizes were reported as mean differences (MD) with 95% confidence intervals (CI).
  3. 03HumanSystematic reviewSafety outcome

    In reviewed patients with obesity and knee osteoarthritis, semaglutide showed a favourable serious-adverse-event safety profile (printed effect 0.21,95% CI -0.46 to 0.88); original reference, signed clinical direction and effect units were unstated.

    In plain wordsIn obesity and knee osteoarthritis, semaglutide showed a favourable safety profile; the signed effect and original comparison were unstated.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedAdverse event risk
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Printed safety effect
    0.21
    original effect reference and units unstated
    95% CI
    −0.46 to 0.88
    safety effect

    Source sentences

    Summary
    In terms of safety, usual care exhibited the lowest risk of adverse events, with liraglutide (0.09, 95% CI - 0.74, 0.92) and semaglutide (0.21, 95% CI - 0.46, 0.88) also showing favorable safety profiles.
    4 context sentences
    Summary · context
    This study aimed to compare the efficacy and safety of antidiabetic drugs for managing pain and adverse events in obese KOA patients through a network meta-analysis of randomized controlled trials (RCTs).
    Summary · context
    A systematic search of multiple databases identified relevant RCTs on antidiabetic drugs for KOA.
    Summary · context
    Treatment efficacy was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score improvement, and safety was evaluated based on the incidence of serious adverse events.
    Summary · context
    The Surface Under the Cumulative Ranking Curve (SUCRA) scores were used to rank the treatments, and effect sizes were reported as mean differences (MD) with 95% confidence intervals (CI).
  4. 04HumanSystematic reviewEfficacy outcome

    In reviewed patients with obesity and knee osteoarthritis, semaglutide was listed after metformin and metformin-phosphatidylcholine for pain-relief effect size; no native numerical SUCRA rank or pairwise ranking-difference coefficient was reported.

    In plain wordsIn obesity and knee osteoarthritis, semaglutide followed metformin and metformin/phosphatidylcholine in network pain-relief ordering; no native SUCRA score was reported.

    Peptide
    Semaglutide
    Outcome
    Not applicableWOMAC pain-relief network ordering
    Study

    n: not reported in source

    Comparator
    Metformin and metformin-phosphatidylcholine in the network
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    For pain relief, metformin demonstrated the largest effect size with a mean difference of - 1.13 (95% CI - 1.48, - 0.78) compared to usual care, followed by Metformin-Phosphatidylcholine (MFPH) (- 0.92, 95% CI - 1.70, - 0.13) and semaglutide (- 0.90, 95% CI - 1.48, - 0.32).
    3 context sentences
    Summary · context
    This study aimed to compare the efficacy and safety of antidiabetic drugs for managing pain and adverse events in obese KOA patients through a network meta-analysis of randomized controlled trials (RCTs).
    Summary · context
    A systematic search of multiple databases identified relevant RCTs on antidiabetic drugs for KOA.
    Summary · context
    The Surface Under the Cumulative Ranking Curve (SUCRA) scores were used to rank the treatments, and effect sizes were reported as mean differences (MD) with 95% confidence intervals (CI).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.